Compare ALEMBIC with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs DR. REDDYS LAB - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC DR. REDDYS LAB ALEMBIC/
DR. REDDYS LAB
 
P/E (TTM) x 59.5 34.8 170.8% View Chart
P/BV x 5.1 4.8 107.6% View Chart
Dividend Yield % 0.2 0.6 35.7%  

Financials

 ALEMBIC   DR. REDDYS LAB
EQUITY SHARE DATA
    ALEMBIC
Mar-18
DR. REDDYS LAB
Mar-20
ALEMBIC/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs723,363 2.1%   
Low Rs342,352 1.4%   
Sales per share (Unadj.) Rs4.71,054.2 0.4%  
Earnings per share (Unadj.) Rs6.1121.9 5.0%  
Cash flow per share (Unadj.) Rs6.2190.2 3.3%  
Dividends per share (Unadj.) Rs0.2025.00 0.8%  
Dividend yield (eoy) %0.40.9 43.2%  
Book value per share (Unadj.) Rs40.7938.7 4.3%  
Shares outstanding (eoy) m267.03166.17 160.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x11.32.7 415.6%   
Avg P/E ratio x8.723.4 37.0%  
P/CF ratio (eoy) x8.515.0 56.4%  
Price / Book Value ratio x1.33.0 42.8%  
Dividend payout %3.320.5 16.0%   
Avg Mkt Cap Rs m14,139474,831 3.0%   
No. of employees `000NA21.7 0.0%   
Total wages/salary Rs m20733,802 0.6%   
Avg. sales/employee Rs ThNM8,091.0-  
Avg. wages/employee Rs ThNM1,561.3-  
Avg. net profit/employee Rs ThNM935.8-  
INCOME DATA
Net Sales Rs m1,255175,170 0.7%  
Other income Rs m3706,206 6.0%   
Total revenues Rs m1,625181,376 0.9%   
Gross profit Rs m11124,421 0.5%  
Depreciation Rs m3811,348 0.3%   
Interest Rs m2983 0.2%   
Profit before tax Rs m44218,296 2.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,212561 216.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m24-1,403 -1.7%   
Profit after tax Rs m1,63020,260 8.0%  
Gross profit margin %8.913.9 63.5%  
Effective tax rate %5.4-7.7 -70.7%   
Net profit margin %129.811.6 1,122.7%  
BALANCE SHEET DATA
Current assets Rs m1,867125,991 1.5%   
Current liabilities Rs m59172,141 0.8%   
Net working cap to sales %101.630.7 330.7%  
Current ratio x3.21.7 180.8%  
Inventory Days Days9473 129.0%  
Debtors Days Days74105 70.2%  
Net fixed assets Rs m1,79183,854 2.1%   
Share capital Rs m534831 64.3%   
"Free" reserves Rs m10,324155,157 6.7%   
Net worth Rs m10,858155,988 7.0%   
Long term debt Rs m411,304 3.2%   
Total assets Rs m11,591232,253 5.0%  
Interest coverage x260.919.6 1,330.2%   
Debt to equity ratio x00 45.4%  
Sales to assets ratio x0.10.8 14.4%   
Return on assets %14.19.1 153.9%  
Return on equity %15.013.0 115.6%  
Return on capital %15.212.6 120.4%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1984,193 0.0%   
Fx outflow Rs m26439,616 0.7%   
Net fx Rs m-24444,577 -0.5%   
CASH FLOW
From Operations Rs m23629,841 0.8%  
From Investments Rs m-224-4,923 4.6%  
From Financial Activity Rs m-27-25,159 0.1%  
Net Cashflow Rs m-15-266 5.6%  

Share Holding

Indian Promoters % 64.0 25.5 251.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 5.4 3.7%  
FIIs % 9.7 35.3 27.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 26.1 15.3 170.6%  
Shareholders   54,701 75,885 72.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   GLENMARK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  DIVIS LABORATORIES  UNICHEM LAB  

Compare ALEMBIC With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Mar 5, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE ALEMBIC WITH

MARKET STATS